Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
J Hallin, V Bowcut, A Calinisan, DM Briere, L Hargis… - Nature medicine, 2022 - nature.com
Recent progress in targeting KRASG12C has provided both insight and inspiration for
targeting alternative KRAS mutants. In this study, we evaluated the mechanism of action and …
targeting alternative KRAS mutants. In this study, we evaluated the mechanism of action and …
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
J Hallin, V Bowcut, A Calinisan, DM Briere… - Nature …, 2022 - pubmed.ncbi.nlm.nih.gov
Recent progress in targeting KRAS G12C has provided both insight and inspiration for
targeting alternative KRAS mutants. In this study, we evaluated the mechanism of action and …
targeting alternative KRAS mutants. In this study, we evaluated the mechanism of action and …
[引用][C] Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
J Hallin, V Bowcut, A Calinisan, DM Briere, L Hargis… - Nat. Med., 2022 - osti.gov
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor.
J Hallin, V Bowcut, A Calinisan, DM Briere… - Nature …, 2022 - europepmc.org
Recent progress in targeting KRAS G12C has provided both insight and inspiration for
targeting alternative KRAS mutants. In this study, we evaluated the mechanism of action and …
targeting alternative KRAS mutants. In this study, we evaluated the mechanism of action and …